Ifenprodil

Algernon Pharmaceuticals to Move Forward with Psychedelic Drug DMT Stroke Research Program as its Lead Asset

Retrieved on: 
Monday, April 1, 2024
Neuroplasticity, Stroke, Diagnosis, Depression, Plasma, CHDR, Rat, Patient, Research, Biomarker, DMT, AGN, Ifenprodil, Brain, Clinical trial, Safety, Algernon, USD, Pharmaceutical industry

Algernon established Algernon NeuroScience (AGN Neuro), a wholly owned subsidiary, to advance the research and development of the DMT stroke program in 2023.

Key Points: 
  • Algernon established Algernon NeuroScience (AGN Neuro), a wholly owned subsidiary, to advance the research and development of the DMT stroke program in 2023.
  • AGN Neuro has completed a feasibility study and has finalized its clinical trial design for a 40 patient Phase 2a DMT Stroke study.
  • The Phase 2a human stroke trial will study an intravenous sub-psychedelic dose of DMT in patients who are hospitalized after having suffered an acute ischemic stroke.
  • “Algernon is a global leader in this important area of research, and we look forward to further advancing the stroke program through our planned Phase 2a DMT Stroke study.”
    Subjects with a confirmed diagnosis of ischemic stroke will be randomized in blinded fashion to receive either DMT or placebo.

Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position

Retrieved on: 
Wednesday, March 27, 2024
Algernon, Brain, Drug discovery, Letter, NMDA, Acquisition, Patient, AGN, Ifenprodil, IPF, Idiopathic pulmonary fibrosis, USD, Chronic cough, Food, Pharmaceutical industry

The Company previously announced on November 22, 2003 that it had signed a Letter of Intent with Seyltx, to acquire Algernon’s Ifenprodil research program.

Key Points: 
  • The Company previously announced on November 22, 2003 that it had signed a Letter of Intent with Seyltx, to acquire Algernon’s Ifenprodil research program.
  • Ifenprodil is an N-methyl-D-aspartate (“NMDA”) receptor antagonist specifically targeting the NMDA type subunit 2B (GluN2B), which prevents glutamate signaling.
  • Ifenprodil is one of Algernon’s lead research programs and represents a novel first-in-class potential treatment for chronic cough.
  • It is thought to interfere with central signalling in the brain, suppressing the urge to cough.

Algernon Pharmaceuticals Announces LOI for the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position

Retrieved on: 
Wednesday, November 22, 2023
Patient, Food, Ifenprodil, U.S. FDA, Drug discovery, FDA, Idiopathic pulmonary fibrosis, AGN, IPF, Brain, USD, LOI, Chronic cough, NMDA, Pharmaceutical industry

Seyltx plans to conduct an Ifenprodil Phase 2b chronic cough study as soon as possible.

Key Points: 
  • Seyltx plans to conduct an Ifenprodil Phase 2b chronic cough study as soon as possible.
  • As stated in the LOI, Algernon’s clinical management team will be available to provide support, oversight and management of the study.
  • Ifenprodil is Algernon’s lead research program and represents a novel first-in-class potential treatment for chronic cough.
  • “We are very pleased to have signed this LOI with Seyltx,” said Christopher J. Moreau, Algernon’s Chief Executive Officer.

Algernon Pharmaceuticals Engages Maxim Group to Explore Spin-Off of its Ifenprodil Phase 2 Chronic Cough Drug Development Program

Retrieved on: 
Tuesday, June 27, 2023
Manchester University NHS Foundation Trust, GSK, Montefiore Medical Center, CSE, University, Critical Care Medicine (journal), RCC, Drug discovery, AGN, NMDA, Brain, Merck & Co., USD, Chronic cough, GSK plc, Acquisition, Patient, Division, Respiratory Medicine, Internal medicine, NHS foundation trust, University of Manchester, Merck, IPF, Regulation of tobacco by the U.S. Food and Drug Administration, P2X3, Idiopathic pulmonary fibrosis, Food, Ifenprodil, Pharmaceutical industry, Bellús

Ifenprodil represents a novel first-in-class potential treatment for chronic cough and is thought to interfere with central signaling in the brain, suppressing the urge to cough.

Key Points: 
  • Ifenprodil represents a novel first-in-class potential treatment for chronic cough and is thought to interfere with central signaling in the brain, suppressing the urge to cough.
  • Patients with IPF are usually excluded from trials in refractory chronic cough (“RCC”), and cough in this population is regarded as extremely difficult to treat.
  • Algernon previously announced on January 14, 2022, that it had received positive feedback from the U.S. Food and Drug Administration at its pre-Investigational New Drug (pre-IND) meeting for its investigation of Ifenprodil solely for the treatment of chronic cough.
  • She runs a multi-disciplinary research team whose focus is on understanding mechanisms underlying pathological cough and a regional clinical service seeing patients with refractory chronic cough.

Algernon Pharmaceuticals Appoints Dr. Peter Dicpinigaitis to Chronic Cough Advisory Board

Retrieved on: 
Wednesday, January 11, 2023
AGN, Physician, BLU, Albert Einstein College of Medicine, Education, Internal medicine, Biochemistry, Montefiore Medical Center, Division, American College, CSE, P2X3, Mount Sinai Medical Center, Critical Care Medicine (journal), Critical care, Conference, Patient, American College of Chest Physicians, Chronic cough, European Respiratory Society, Cough, Acquisition, USD, Merck & Co., Ifenprodil, Pharmaceutical industry, New York University, Medicine, Gefapixant, NYU

Dr. Dicpinigaitis will be advising the Company on its planned 180 patient, Phase 2b chronic cough study of NP-120 (Ifenprodil).

Key Points: 
  • Dr. Dicpinigaitis will be advising the Company on its planned 180 patient, Phase 2b chronic cough study of NP-120 (Ifenprodil).
  • Dr. Dicpinigaitis is board-certified in Internal Medicine, Pulmonary Diseases and Critical Care Medicine.
  • “We are very pleased that Dr. Dicpinigaitis has joined Algernon as a medical advisor,” said Christopher J. Moreau, CEO of Algernon Pharmaceuticals.
  • At the time, Gefapixant had interim data from a Phase 2b dose-escalation study in refractory chronic cough.

Algernon Pharmaceuticals Announces Plans for a 180 Patient Phase 2b Chronic Cough Study of Ifenprodil

Retrieved on: 
Monday, January 9, 2023
IND, AGN, Brain, Element, University, Merck, Idiopathic pulmonary fibrosis, CSE, P2X3, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, FDA, Respiratory Medicine, Idiopathic disease, University of Manchester, Merck & Co., Patient, U.S. FDA, Food, Manchester University NHS Foundation Trust, Chronic cough, Drug discovery, NHS foundation trust, Cough, Acquisition, NMDA, USD, IPF, Ifenprodil, Pharmaceutical industry, Gefapixant, Algernon

Ifenprodil represents a novel first-in-class potential treatment for chronic cough and is thought to interfere with central signalling in the brain, suppressing the urge to cough.

Key Points: 
  • Ifenprodil represents a novel first-in-class potential treatment for chronic cough and is thought to interfere with central signalling in the brain, suppressing the urge to cough.
  • Patients with IPF are usually excluded from trials in refractory chronic cough, and cough in this population is regarded as extremely difficult to treat.
  • While the Company originally planned to focus on IPF in a Phase 2b study, Algernon has now decided to pursue a chronic cough study first, and to delay planning its IPF Phase 2b study for Ifenprodil until a later date.
  • At the time, Gefapixant had interim data from a Phase 2b dose-escalation study in refractory chronic cough.

Algernon Pharmaceuticals Forms Private Subsidiary to Advance Company’s Psychedelic DMT Stroke Program; Files Form 1-A Offering Statement with U.S. SEC for Regulation A+ Offering

Retrieved on: 
Tuesday, January 3, 2023
IPO, Marketing, Calendar, Stroke, DMT, Research, USD, Broker-dealer, AGN, Ifenprodil, CSE, Reg, IPF, Medicine, Security (finance)

The Company has valued the psychedelic DMT research program at USD $20M and has formally completed an asset transfer and trademark license agreement, transferring all DMT research program assets into AGN Neuro.

Key Points: 
  • The Company has valued the psychedelic DMT research program at USD $20M and has formally completed an asset transfer and trademark license agreement, transferring all DMT research program assets into AGN Neuro.
  • The Company has also signed a management agreement with AGN Neuro to provide all day-to-day operations, as well as management of the DMT stroke clinical trial program.
  • The capital raised will be used for research, development, and program management costs related to the completion of a Phase 1 and Phase 2a DMT stroke study.
  • Reg A+ financings are an SEC-regulated funding mechanism allowing issuers an alternative way to access the public markets, while reducing offering costs in the process.

Algernon Pharmaceuticals Files for Orphan Designation with the U.S. FDA for Ifenprodil as a Treatment of IPF

Retrieved on: 
Monday, September 19, 2022
Cough, IPF, Chronic kidney disease, Fibrosis, FDA, Neutrophil, Algernon, NMDA, Company, Degenerative disease, Stroke, Patient, Scar, CSE, Quality of life, AGN, Tissue, Drug development, Research, GLOBE, DMT, Mortality, Chronic cough, Pharmaceutical industry, Ifenprodil

As a result, the Company further announces it has filed a request for Orphan Designation with the United States Food and Drug Administration (U.S. FDA) for the use of Ifenprodil as a treatment for IPF.

Key Points: 
  • As a result, the Company further announces it has filed a request for Orphan Designation with the United States Food and Drug Administration (U.S. FDA) for the use of Ifenprodil as a treatment for IPF.
  • Supporting the development and evaluation of new treatments for rare diseases through orphan designation is a priority for the U.S. FDA and other jurisdictions (Europe) that have similar orphan programs.
  • Orphan designation qualifies sponsors for incentives including tax credits for qualified clinical trials, exemption from user fees, and a potential seven years of market exclusivity after approval.
  • Algernon will continue working to accelerate the development of Ifenprodil as a potential new therapy for IPF with cough.

Algernon Pharmaceuticals’ Largest Shareholder AlphaNorth Asset Management Increases Ownership Position

Retrieved on: 
Tuesday, August 23, 2022
CSE, Weakness, DMT, Investment, GLOBE, Reward, Stroke, Company, Ifenprodil, AGN, Security (finance), Pharmaceutical industry

VANCOUVER, British Columbia, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the Company or Algernon) is pleased to announce that its largest shareholder, AlphaNorth Asset Management (AlphaNorth), has increased its ownership position in the Company by acquiring 150,000 shares in the recent private placement financing.

Key Points: 
  • VANCOUVER, British Columbia, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the Company or Algernon) is pleased to announce that its largest shareholder, AlphaNorth Asset Management (AlphaNorth), has increased its ownership position in the Company by acquiring 150,000 shares in the recent private placement financing.
  • We believe the weakness in the recent share price has provided a great opportunity to increase our position in Algernon, said Steve Palmer CEO of AlphaNorth.
  • Our increased investment confirms our support for the drug pipeline they are developing as well as our strong belief in management.
  • Founded in 2007, AlphaNorth Asset Management (AlphaNorth) is a Toronto-based investment manager.

Algernon Pharmaceuticals Hits Co-Primary Endpoint in its Phase 2 Study of Ifenprodil for Idiopathic Pulmonary Fibrosis and Chronic Cough

Retrieved on: 
Monday, July 18, 2022
Patent, University, Manchester University NHS Foundation Trust, NHS foundation trust, Respiratory Medicine, Disease, CEO, Atmosphere, Idiopathic pulmonary fibrosis, Patient, CSE, Method, IPF, FVC, Breakthrough therapy, Interstitial lung disease, Serum, GLOBE, Cough, University of Manchester, AGN, NMDA, Canadian Intellectual Property Office, Vital capacity, Vertigo, Company, Risk, Mortality, Optimism, Death, Lung, HIV disease progression rates, Appetite, Neutrophil, Tissue, FDA, Degenerative disease, McMaster University, Chronic cough, Pharmaceutical industry, Fine chemical, Medical device, Surveying, Ifenprodil

Ifenprodil represents a novel first in class treatment for both IPF and chronic cough.

Key Points: 
  • Ifenprodil represents a novel first in class treatment for both IPF and chronic cough.
  • The primary endpoint of the IPF part of the study was the proportion of patients who responded.
  • Although the primary cough endpoint does not reach statistical significance, the reductions in cough counts, particularly the median cough counts, are suggestive of a beneficial effect.
  • 3101853, for the treatment of interstitial lung disease with Ifenprodil, entitled Compositions and Methods for Treating Idiopathic Pulmonary Fibrosis.